{"nctId":"NCT00432458","briefTitle":"Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma","startDateStruct":{"date":"2003-07"},"conditions":["Multiple Myeloma and Plasma Cell Neoplasm"],"count":68,"armGroups":[{"label":"Arm I: Thal/ZLD","type":"EXPERIMENTAL","interventionNames":["Drug: Thalidomide","Drug: zoledronic acid"]},{"label":"Arm II: ZLD","type":"EXPERIMENTAL","interventionNames":["Drug: zoledronic acid"]}],"interventions":[{"name":"Thalidomide","otherNames":[]},{"name":"zoledronic acid","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Diagnosis of multiple myeloma (MM)\n\n  * Previously untreated asymptomatic disease\n  * No requirement for immediate chemotherapy for active MM, such as hypercalcemia from myeloma or painful bone lesions\n* No solitary plasmacytoma\n* Measurable or evaluable disease as defined by one of the following:\n\n  * Serum monoclonal protein ≥ 1.0 g by protein electrophoresis\n  * More than 200 mg of monoclonal protein in the urine by 24-hour electrophoresis\n  * Measurable soft tissue plasmacytoma by physical exam with ruler or by MRI or positron emission tomography/CT scan\n\n    * If the only measurable lesion is the plasmacytoma, it must be ≥ 1.5 cm in 1 dimension\n* Must have ≥ 10% plasma cells as measured on the bone marrow aspirate, bone marrow biopsy, or labeling index\n* No amyloidosis\n\nPATIENT CHARACTERISTICS:\n\n* Performance status 0-2\n* Absolute neutrophil count ≥ 1,500/mm³\n* Platelet count ≥ 100,000/mm³\n* Hemoglobin ≥ 8.0 g/dL\n* Creatinine ≤ 2.0 mg/dL (elevation above normal range should not be felt to be related to myeloma)\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use 2 methods of effective contraception 4 weeks before, during, and for 4 weeks after completion of study treatment\n* No uncontrolled infection\n* No other active malignancy\n* No New York Heart Association class III or IV heart disease\n* No pre-existing neuropathy ≥ grade 2\n* No concurrent major dental work\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* Prior corticosteroids (for nonmalignant disorders) allowed\n* Prior therapy with experimental agents not shown to have significant activity in MM, such as clarithromycin, dehydroepiandrosterone, and anakinra allowed\n* No prior thalidomide or corticosteroids for MM\n* No more than 3 doses of IV zoledronate or pamidronate within the past 12 months\n* At least 3 months since prior radiotherapy, including radiotherapy for solitary plasmacytoma\n* No concurrent oral bisphosphonate therapy for osteoporosis","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Disease Progression (TTP)","description":"Time to disease progression (TTP) was defined as the time from randomization to the earliest documentation of disease progression. Participants were followed for a maximum of 5 years from registration. The median OS with 95% CI was estimated using the Kaplan Meier method, a two-sided (stratified) log-rank test was calculated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":null},{"groupId":"OG001","value":"1.2","spread":null}]}]}]},{"type":"SECONDARY","title":"12-month Progression-free Survival (PFS)","description":"PFS at 12 months is a dichotomized outcome indicating whether or not a participant was progression free (and alive) at 12 months from the date of randomization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Confirmed Response (Complete Response [CR], Very Good Partial Response [VGPR] or Partial Response [PR]) on Two Consecutive Evaluations at Least 2 Weeks Apart in the First 12 Months of Treatment","description":"Response is defined as follows:\n\n* CR: Complete disappearance of M-protein from serum \\& urine on immunofixation, \\<5% plasma cells in bone marrow (BM)\n* VGPR: \\>=90% reduction in serum M-component; Urine M-Component \\<100 mg per 24 hours; \\<=5% plasma cells in BM\n* PR: \\>= 50% reduction in serum M-Component and/or Urine M-Component \\>= 90% reduction or \\<200 mg per 24 hours; or \\>= 50% decrease in difference between involved and uninvolved FLC levels","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response (Complete Response, Partial Response, and Very Good Partial Response)","description":"Duration of response (DOR) is defined as the time from first documentation of response (CR, VGPR or PR) to disease progression. The median DOR with 95% CI was estimated using the Kaplan Meier method","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Subsequent Treatment","description":"Time to subsequent treatment (TTS) was defined as time from end of active (protocol) treatment to the start of subsequent treatment for participants with progressive disease. The median TTS with 95% CI was estimated using the Kaplan Meier method","classes":[]},{"type":"SECONDARY","title":"Time to Treatment Failure","description":"Time to treatment failure (TTF) was defined as the time from randomization to the date at which the patient was removed from (protocol) treatment due to disease progression, unacceptable toxicity, participant refusal or death. The median TTF with 95% CI was estimated using the Kaplan Meier method","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.5","spread":null},{"groupId":"OG001","value":"11.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Severe (Grade 3, 4 or 5) Adverse Events","description":"Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 2.\n\nDescription of Grades:\n\nGrade 1: Mild Grade 2: Moderate Grade 3: Severe Grade 4: Life-threatening Grade 5: Death","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":35},"commonTop":["Fatigue","Peripheral sensory neuropathy","Constipation","Depressed level of consciousness","Rash/Desquamation"]}}}